TB-500: What Athletes Use It For & What Research Actually Shows
TB-500 is frequently paired with BPC-157 in recovery stacks, and the two are often described as interchangeable. They are not. TB-500 works through actin regulation and cell migration rather than angiogenesis, and its evidence base has a different shape.
What TB-500 Is
TB-500 is a synthetic peptide corresponding to an active fragment of thymosin beta-4, a naturally occurring protein present in most human cells and in high concentration in wound fluid and platelets. Vendors often use 'TB-500' and 'thymosin beta-4' interchangeably; they are related but not identical, and the distinction matters when interpreting research conducted on full-length TB4.
Mechanism: Actin Sequestration and Cell Migration
Thymosin beta-4 is the primary actin-sequestering molecule in mammalian cells. By regulating the pool of available actin monomers, it influences cytoskeletal reorganization — which is what a cell must do to migrate. In wound healing, that translates to faster movement of endothelial cells, keratinocytes and stem cells into damaged tissue. Downstream effects described in the literature include reduced inflammatory signaling and modulation of collagen deposition.
Animal and Preclinical Research
TB4 has been studied in dermal wound models, corneal injury, and cardiac repair after induced infarction, where it improved functional recovery in rodent models. Those cardiac findings drove full-length TB4 into early human trials for other indications. The research quality here is generally higher than for BPC-157, because TB4 is an endogenous protein with academic interest independent of the athletic market.
Human Efficacy for Athletic Recovery: Not Established
No randomized human trial has tested TB-500 for tendon, ligament or muscle recovery in athletes. Early-phase human work on full-length thymosin beta-4 exists in dermatology and ophthalmology. Extrapolating from a corneal wound trial to a hamstring strain is a leap the data does not support.
Protocols Reported in Practice
Community protocols commonly cite a loading phase of 2–2.5 mg twice weekly for four to six weeks, followed by a lower maintenance frequency. TB-500 is typically given subcutaneously and, unlike BPC-157, is usually described as systemic rather than site-specific because of its distribution profile. Again: no human dose-finding study supports these numbers.
WADA Status: Prohibited
TB-500 is explicitly prohibited under WADA's S2 category (peptide hormones, growth factors and related substances) and is detectable in anti-doping testing. Multiple athletes have received sanctions for it, including in equestrian and endurance sport.
Verification: Critical for This Molecule
TB-500 is among the more frequently misrepresented peptides in tested samples — partly because 'TB-500' and 'thymosin beta-4' are used loosely, so a vial may contain a different fragment than expected. Mass spectrometry resolves identity; HPLC resolves purity and concentration. Without both, you are trusting a label written by an unregulated supplier.
Frequently Asked Questions
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic fragment corresponding to an active region of the full-length thymosin beta-4 protein. Much of the cited research used full-length TB4.
Is TB-500 banned in sport?
Yes. It is prohibited under WADA S2 at all times and is detectable in testing.
Does TB-500 work for injuries?
Animal wound and cardiac repair models are supportive. No published human trial has tested it for athletic injury recovery.
References
Report a Safety Issue
If you've experienced health issues after using this peptide, please report it. Your report helps us track safety issues and protect other users.
Report Adverse Event